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tions in erythrocyte zinc protoporphyrin (130 6 32 vs. 72 6Erythropoietin hyporesponsiveness: From iron deficiency to
19 mmol/mol heme, P , 0.05) and monthly rHuEPO dose (24.2 6iron overload. Iron deficiency is the most frequently encoun-
4.5 vs. 16.8 6 3.4 3 103 units, P , 0.05) at the end of study.tered cause of suboptimal response to recombinant human
It is speculated that ascorbate supplementation not only facili-erythropoietin (rHuEPO). Carefully assessing iron status is of
paramount importance in chronic renal failure patients prior tates the iron release from storage sites and its delivery to
to or during rHuEPO therapy. Because there is great need for hematopoietic tissues, but also increases iron utilization in ery-
iron in the EPO-stimulated erythroid progenitors, it is essential throid cells. Our study provides a more complete understanding
that serum ferritin and transferrin saturation levels should be of the pathogenesis of iron overload-related anemia and the
maintained over 300 mg/liter and 30%, respectively. Investiga- development of an adjuvant therapy, intravenous ascorbic acid,
tors have shown that oral iron is unlikely to keep pace with to the existing treatments.
the iron demand for an optimal rHuEPO response in uremics.
Therefore, patients with iron deficiency will always require
intravenous iron therapy. The early and prompt iron supple-
mentation can lead to reductions in rHuEPO dose and hence Renal anemia has been effectively alleviated or re-
cost. After the iron deficiency has been corrected or excluded, versed by recombinant human erythropoietin (rHuEPO)
we must remember all of the possible causes of hyporespon- in the majority of end-stage renal disease (ESRD) pa-siveness in every rHuEPO-treated patient. As dose require-
tients [1–3]. Nowadays, most dialysis units set their targetments vary, it is not clear which dose of rHuEPO causes this
hemoglobin between 10 and 12 g/dl. Achievement of thishyporesponsiveness. However, if the patient with iron repletion
does not respond well after the induction period, the major target is significantly associated with an improvement in
causes blunting the response to rHuEPO should be investi- the quality of life, a reduction in the need for blood trans-
gated. Most factors are reversible and remediable, except resis-
fusion, and an avoidance of transfusion-related sequelaetant anemia associated with hemoglobinopathy or bone mar-
[2–6]. The beneficial effects of increasing hemoglobin onrow fibrosis, which requires a further increase in the rHuEPO
dose. By means of early detection and correction of the possible left ventricular hypertrophy [7, 8] and the correction of
causes, the goal of increasing therapeutic efficacy can be malnutrition [9–11] can also reduce the morbidity and
achieved. Iron overload may lead to an enhanced risk for infec- mortality in dialysis patients on rHuEPO therapy.tion, cardiovascular complication, and cancer. Over-treatment
While the efficacy of rHuEPO treatment is impressive,with iron should be avoided in dialysis patients, despite the
poor responses have been documented [12–14]. Severalfact that the safe upper limit of serum ferritin to avoid iron
overload is not clearly defined. On the other hand, functional studies have advocated the evaluation of patients with
iron deficiency may develop even when serum ferritin levels rHuEPO hyporesponsiveness [15–20], but the underly-
are increased. Controversy remains as to whether intravenous
ing mechanism is not yet fully understood. The incre-iron therapy can overcome this form of hyporesponsiveness in
ments of effective erythropoiesis by rHuEPO are doseiron-overloaded patients. Moreover, a treatment option of iron
supplementation is not warranted in these patients, as the po- dependent over doses ranging between 25 and 500 U/kg
tential hazards of iron overload will be worsened. We demon- i.v. three times a week in patients with chronic renal
strated that the mean hematocrit significantly increased from failure [2, 21]. Ninety-five percent of the patients will25.1 6 0.9% to 31 6 1.2% after eight weeks of intravenous
respond to high doses of rHuEPO, and only 5% of pa-ascorbate therapy (300 mg three times a week) in 12 hemodialysis
tients exhibit resistance to high-dose rHuEPO withoutpatients with serum ferritin levels of more than 500 mg/liter. The
enhanced erythropoiesis paralleled with a rise in transferrin any obvious reasons. The response varies with doses rang-
saturation (27.8 6 2.5% vs. 44.8 6 9.5%, P , 0.05) and reduc- ing from 120 to 150 U/kg/week [2]. This variation remains
obscure, and several factors could be involved. Iron defi-
ciency is the most frequently encountered cause [22–24],Key words: anemia, rHuEPO, chronic renal failure, dialysis, iron sup-
plementation. whereas other factors [25–40] such as infections, chronic
inflammations, aluminum toxicity, secondary hyperpara- 1999 by the International Society of Nephrology
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Table 1. Cut-off values of iron metabolism indices for diagnosis of iron deficiency
Index Reference
Serum ferritin lg/liter
Pre-rHuEPO era
50 Gokal et al, 1979 [42]
55 Lynn et al, 1981 [43]
70 Blumberg et al, 1983 [44]
80 Bell et al, 1980 [45]
Era of rHuEPO
30 Van Wyck et al, 1989 [22]
100 Eschbach et al, 1989 [21]; Ho¨rl et al, 1996 [16]
120 Mirahmadi et al, 1977 [46]
160 Docci et al, 1983 [47]
191 Allegra et al, 1991 [48]
200 Erslev, 1991 [49]; Schaefer and Schaefer, 1992 [50]; Sunder-Plassmann and Ho¨rl, 1994 [51]
300 Tarng et al, 1995 [24]; Fishbane et al, 1995 [52]; Eschbach, 1996 [53]; Nissenson, 1996 [19]; Tarng and Huang, 1997 [20]
Transferrin saturation %
16 Bainton and Finch, 1964 [54]
20 Eschbach et al, 1987 [2]; Schaefer et al, 1989 [3]; Macdougall et al, 1989 [55]; Casati et al, 1991 [56]; Gru¨tzmacher
et al, 1992 [57]; Ho¨rl et al, 1995 [17] and 1996 [58]
25 Tarng et al, 1995 [24] and 1997 [59]; Tarng and Huang, 1997 [32]
30 Nissenson, 1996 [19]; Tarng and Huang, 1997 [20]
Percentage of hypochromic
RBC %
6 Braun et al, 1997 [60]
10 Macdougall, 1992 [23]; Schaefer and Schaefer, 1992 [50]; Golan et al, 1994 [61]; Ho¨rl et al, 1995 [17] and 1996 [58]
Erythrocyte zinc protopor-
phyrin lmol/mol heme
40 Hastka et al, 1991 [62]
90 Fishbane and Lynn, 1995 [63]
Soluble transferrin
receptor lg/liter
3500 Beguin et al, 1993 [64]; Danielson, 1995 [65]
thyroidism, bone marrow dysfunction, occult blood loss, studies and discuss the issues related to (a) diagnosis and
hemolysis, and hemoglobinopathy are not uncommon. treatment of iron deficiency, (b) other factors blunting
Recombinant human EPO therapy is expensive and the response to rHuEPO in iron-replete state, and (c)
restrained in some countries because of economic fac- intravenous ascorbic acid as an adjuvant therapy in iron-
tors. The cost of rHuEPO therapy is certainly influenced overloaded patients with poor response to rHuEPO.
by hyporesponsiveness to this hormone. Except refractory
anemia associated with bone marrow fibrosis or hemo-
IRON DEFICIENCYglobinopathy, most factors leading to poor rHuEPO re-
There are three components for proper erythropoiesissponse are reversible and remediable. Based on the cost
in dialysis patients: (1) rHuEPO, a stimulating factor toeffectiveness, it is rational to explore the treatable factors
accelerate hematopoietic activity; (2) an adequate ironbefore increasing the doses when confronted with a dial-
reserve, a prerequisite for iron supply; and (3) an effec-ysis patients with rHuEPO hyporesponsiveness. By means
tive iron mobilization/transport, a pivotal factor for ironof early detection and correction of the possible causes,
utilization. Because adequate iron stores and iron avail-the goals of reducing the rHuEPO dose and increasing
ability are of great importance for the patient to get atherapeutic efficacy can be achieved.
prompt response to rHuEPO, iron status should be firstSometimes the reasons for inadequate response to
assessed before or during rHuEPO treatment. A numberrHuEPO are not easily identified, and multiple factors
of laboratory tests are useful in determining iron statusmay be involved. Because iron deficiency is the most
in patients receiving rHuEPO (Table 1), but an optimalcommon and easily treated cause, it is important to un-
method for the diagnosis of iron deficiency is still contro-derstand the iron metabolism in erythropoiesis and es-
versial. Serum ferritin is known as a noninvasive proce-tablish guidelines for assessment of iron status in ESRD
dure, and its value is an indirect index of total body ironpatients on rHuEPO treatment. In this article, we focus
stores in healthy individuals [41] and patients on chronicon the issue of hyporesponsiveness to rHuEPO. The
dialysis [16, 19, 20–22, 24, 42–53]. On the other hand,iron stores in ESRD patients are classified into three
iron deficiency does not always mean that iron storescategories: iron deficiency, iron repletion, and iron ex-
cess. Using this classification, we present our published are diminished. The availability of iron can be reduced,
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Fig. 1. Flow chart to assess iron status in chronic
renal failure patients undergoing recombinant
human erythropoietin treatment or with erythro-
poietin hyporesponsiveness.
a situation known as functional iron deficiency. The pa- Based on our studies [20, 24, 32, 59] and the works of
others [19, 52, 53, 67, 68], a flow chart is proposed torameters for determining a functional iron deficiency are
the transferrin saturation (TS) [2, 3, 16, 19, 20, 24, 32, evaluate iron status in dialysis patients receiving rHuEPO
treatment (Fig. 1). Our study showed that a serum ferri-54–59], percentage of hypochromic red cells [16, 23, 50,
58, 60, 61], erythrocyte zinc protoporphyrin (ZPP) [62, tin level of 300 mg/liter has a 100% ability to separate
patients with or without initial resistance to rHuEPO63], serum transferrin receptor [64, 65], and erythrocyte
ferritin [66]. Despite that classic methods lack sensitivity [24]. A serum ferritin level of more than 300 mg/liter
means that body iron stores are adequate or increased.and specificity, new methods are sophisticated and not
generally available. Nowadays, serum ferritin and TS are It is essential that serum ferritin should be maintained
over 300 mg/liter because there is great need for iron instill the most widely accepted tests for clinical practice.
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Fig. 2. Iron status in patients receiving hemodi-
alysis (N 5 13,396, j) and continuous ambula-
tory peritoneal dialysis (N 5 804, h) according
to 1996 Annual Report on the Management of
End-Stage Renal Failure in Taiwan [69].
the rHuEPO-stimulated erythroid progenitor cells [19, suggests that iron absorption is impaired in hemodialysis
[74] or CAPD [75] patients receiving rHuEPO when20, 24, 52, 53, 67]. A serum ferritin level of less than 100
compared with nonuremics. Moreover, gastrointestinalmg/liter is defined as absolute iron deficiency [17, 21,
upset, binding to phosphate binders, and noncompliance68]. Between 100 and 300 mg/liter, however, the serum
may all reduce the efficacy of oral iron therapy. Investiga-ferritin level is not predictive of which patients respond
tors also demonstrate that oral iron is unlikely keep paceto intravenous iron therapy with an improvement in
with the iron demand for optimal rHuEPO responseerythropoiesis [24, 32, 59]. TS is a good indicator for the
[3, 55, 56, 76, 77]. Therefore, patients with absolute orcurrent balance of supply and demand of plasma iron.
functional iron deficiency will require intensive iron sup-The calculated TS of 30% is a cut-off value for the diag-
plements, almost always in the form of i.v. iron.nosis of functional iron deficiency [19, 20, 52, 67].
Intravenous iron therapy not only maintains ironIn Taiwan, 82% of hemodialysis patients (N 5 16,159)
stores but also enhances the efficacy of rHuEPO therapy.and 66% of continuous ambulatory peritoneal dialysis
Several recent studies demonstrated that the mean(CAPD) patients (N 5 1021) received rHuEPO treat-
rHuEPO dose was reduced from 27% to 71% in patientsment in 1996 [69]. However, the average hematocrit lev-
treated with i.v. iron [50, 52, 59, 78–80]. For hemodialysisels in hemodialysis and CAPD patients were only 26.8%
patients with overt iron deficiency, a commonly used
and 26.5%, respectively. The multivariate analysis re- intensive regimen is 125 or 100 mg iron by i.v. administra-
vealed that iron deficiency, underdialysis, and inade- tion for 10 consecutive treatments (Table 2). Of interest,
quate dose are the major factors of hyporesponsiveness Fishbane and Maesaka declared that the standard 1000
to rHuEPO in the Taiwanese dialysis population. Fur- mg dosing cycle actually may be underestimated [67].
ther analysis of the iron metabolism indices (Fig. 2) Most patients will require more than one cycle of treat-
shows that 51% of hemodialysis patients and 47% of ment [51, 78]. However, the potential hazard of iron
CAPD patients had ferritin levels of less than 300 mg/ therapy should not be disregarded. Intravenous iron
liter, and 30% of hemodialysis patients and 31% of therapy is frequently linked to iron overload with the
CAPD patients had TS of less than 30%. The data are increasing risks of hemosiderosis [85, 86], hepatic or car-
consistent with the finding that iron deficiency, either diac dysfunction [87], and bacterial infection [88]. Be-
absolute or functional, is the most common problem in cause the upper limit of serum ferritin or TS to avoid
iron overload is not clearly defined in dialysis patients,chronic renal failure patients treated with rHuEPO.
high-dose i.v. iron therapy should be used cautiously inIron supplementation in patients on rHuEPO therapy
patients with serum ferritin of more than 100 mg/liter.should be taken into account for three reasons: (a) low
Giving low-dose maintenance therapy in such patientsavailability of dietary iron because of a restriction in
is justified to in order to avoid the inadvertent hazardsdietary protein and an impaired iron absorption by pre-
(Table 2) [24, 55, 59, 89–93]. Additionally, serum ferritinscribed drugs, for example, calcium carbonate [70]; (b)
should be measured serially to ensure that iron storesbody iron reserve reduction [71–73] from blood loss dur-
are adequately repleted after therapy.ing the dialysis procedure, repeated blood sampling for
laboratory tests, and occult loss due to the tendency to
OTHER CAUSES BLUNTING THE RESPONSEbleed; and (c) functional iron deficiency [2, 3, 17, 19, 20,
TO rHuEPO IN THE IRON-REPLETE STATE23, 63, 64] with the anticipated demand exceeding iron
supply released from storage, even when serum ferritin Eschbach defines rHuEPO hyporesponsiveness as fail-
ure to achieve the target hemoglobin in the presence oflevels are normal or increased. A large body of evidence
Tarng et al: Erythropoietin hyporesponsiveness S-111
Table 2. Summaries of intravenous iron schedules in patients of chronic renal failure
Dosing cycle regimen Authors
High-dose aggressive therapy
125 mg 3 10 consecutive treatments Pascual et al, 1991 [81] and 1992 [82]
100 mg 3 10 consecutive treatments Van Wyck et al, 1989 [22], Sunder-Plassmann and Ho¨rl, 1994 [51];
Rosenlo¨f et al, 1995 [83]; Fishbane and Maesaka, 1997 [67]
500 mg weekly or total dose of iron during one single dialysis session Winchester et al, 1995 [84]
200 mg weekly for 4 months Fishbane et al, 1995 [52]
Low-dose maintenance treatment
50 mg twice a week Macdougall et al, 1989 [55]
20 mg in each dialysis session Grannolleras et al, 1991 [89]
40 mg in each dialysis session Tsobanelis et al, 1991 [90]
100 mg every 2 weeks Silverberg, 1996 [91]
200 mg every 4 weeks Silverberg, 1996 [92]
100 mg once a week Tarng et al, 1995 [24] and 1997 [59]
Total dose: (target Hb 2 present Hb) 3 150 mg
62.5 mg per month Navarro et al, 1996 [93]
Total dose: 375 mg
Hb is hemoglobin.
adequate iron stores at a dose of 450 U/kg/week i.v. or should be treated or prevented early whenever possible.
This algorithm is based almost entirely on data from300 U/kg/week subcutaneous within four to six months
or failure to maintain target hemoglobin subsequently patients on hemodialysis receiving rHuEPO, whereas
the same causes of hyporesponsiveness likely apply toat that dose [53]. Despite that different definitions have
been proposed [14, 94–96], this concept is accepted by patients on peritoneal dialysis or predialysis [19].
the National Kidney Foundation’s Dialysis Outcome
Subclinical aluminum toxicityQuality Initiative in the section on inadequate rHuEPO
response [97]. Actually, the individual response is vari- The implications of aluminum toxicity in the genesis
of anemia and resistance to rHuEPO treatment haveable, with doses ranging from 120 to 150 U/kg/week [2,
14, 94]. The reason for this variation in response and the been well documented. A number of proposals about
aluminum-induced anemia have been made: an inhibi-mechanism for suppression of the effect of rHuEPO are
still not known. In dialysis patients with iron repletion, tion of heme-synthetic enzymes [30, 100], an interference
with iron transport by competing for transferrin bindingthe different causes of hyporesponsiveness can be pres-
ent in each patient with a different intensity [18]. These sites [101–103], and hemolysis with increased osmotic
fragility of red cells [104]. These observations are infactors include episodes of inflammations or infections
[25–29], aluminum toxicity [30–32], severe hyperparathy- keeping with the recent reports of resistance to rHuEPO
in aluminum-intoxicated dialysis patients [104–106]. Suchroidism [33], occult blood loss [34], hemolysis [35], hemo-
globinopathy [36–40], and folate or vitamin B12 defi- patients characteristically exhibited microcytic anemia
despite normal iron stores. Nowadays, aluminum-inducedciency [98, 99].
It is not always easy to identify the cause of rHuEPO anemia is more often normocytic than microcytic, except
in cases of severe poisoning. In iron-replete patients,hyporesponsiveness. Thus, a stepwise approach is needed
to investigate patients with a poor response to rHuEPO. desferrioxamine (DFO) therapy can overcome aluminum-
induced rHuEPO hyporesponsiveness, which can be de-Nissenson [19] and Tarng and Huang [20] propose an
algorithm (Fig. 3), from a clinical point of view, so that tected by serum aluminum levels pre- and post-DFO
infusion [107]. Therefore, it is mandatory to monitordiagnoses may be made more concisely and conveniently
and thus unnecessary examinations can be avoided. The serum aluminum levels for early diagnosis.
Our previous study showed that 39 hemodialysis pa-patients are stratified into three groups anemia by check-
ing the mean corpuscular volume: microcytic, normo- tients of iron repletion had no aluminum-related symp-
toms, but the responsiveness to rHuEPO significantlycytic, and macrocytic. When the survey for folate or
vitamin B12 deficiency reveals no abnormality in macro- correlated with serum aluminum concentrations and was
greater in those with lower serum aluminum levels, in-cytic anemia, iron status should be assessed in three
groups. Patients with a serum ferritin of more than 300 cluding basal and 44 hours after DFO infusion [32].
Meanwhile, the post-DFO rise of serum aluminum (DAl)mg/liter and TS of more than 30% do not suggest the
presence of iron deficiency. After iron deficiency has is markedly increased and has a strong inverse correla-
tion with mean corpuscular volume (MCV) in poor re-been corrected or excluded, further studies are needed to
explore other rHuEPO-resistant causes before increasing sponders. Our data corroborates the findings that DAl
may be used as a means of estimating tissue stores [108],the doses (Figs. 1 and 3). The pathological conditions
Tarng et al: Erythropoietin hyporesponsivenessS-112
Fig. 3. Investigation of dialysis patients with hyporesponsiveness to recombinant human erythropoietin treatment. (Reprinted with permission
from Peritoneal Dialysis International.)
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Table 3. Patient characteristics, evolution of the hematocrit and ironand the inverse relationship is due to an inhibitory effect
metabolism indices in hemodialysis patients treated with ascorbicof aluminum on heme synthesis and/or on iron availabil- acid (Study group) or not receiving ascorbic acid
ity [100, 106]. It implies that patients with increased tissue treatment (Control group)
aluminum stores will require a higher rHuEPO dose even Control group Study group
without overt symptoms. DFO therapy provides a ratio-
Number 12 12nale for this form of rHuEPO hyporesponsiveness be- Mean age years 54 6 4 50 6 5
cause aluminum intoxication has been shown to be re- Sex % male 66.7 58.3
Time on hemodialysis months 64 6 13 62 6 10versible by this chelating agent.
Duration of rHuEPO used months 12 6 5 14 6 6
Hematocrit %Thalassemia
baseline 31.5 6 1.5 25.1 6 0.9a
at 8 weeks 31.4 6 2.0 31.0 6 0.6bInvestigators claimed that thalassemic patients on
Ferritin lg/literchronic dialysis exhibit a reduced erythropoietic response
baseline 785 6 185 800 6 250
to rHuEPO as compared with nonthalassemic patients at 8 weeks 750 6 177 720 6 212
Transferrin saturation %[38, 39, 107–111]. Kagan, Sinay-Trieman and Bar-Khayim
baseline 44.9 6 9.8 27.8 6 2.5aanalyzed the rHuEPO requirements in thalassemic dial-
at 8 weeks 43.0 6 9.0 44.8 6 9.5bysis patients from the published literature [39]. They ZPP lmol/mol heme
arbitrarily stratified these patients into a high-dose group baseline 83 6 21.3 130 6 32.4a
at 8 weeks 80 6 20.0 72 6 18.6b($400 U/kg/week) and low-dose group (#250 U/kg/
rHuEPO dose 3 10 3 U/monthweek). The mean maintenance doses of rHuEPO in both baseline 14.7 6 2.9 24.2 6 4.5a
groups were 553 6 70 and 157 6 18 U/kg/week, respec- at 8 weeks 15.0 6 3.1 16.8 6 3.4b
tively. Most patients in the low-dose group cannot achieve Data are expressed as mean 6 standard error of mean. Abbreviations are:
rHuEPO, recombinant human erythropoietin; ZPP, erythrocyte zinc protopor-the hematocrit of 30%. In contrast, our study demon-
phyrin.strated a promising response to low rHuEPO doses in a P , 0.05 vs. controls, between-group comparison by Student’s t-test
b P , 0.05 vs. baseline, within-group comparison by Student’s paired t-testthe correction phase (rHuEPO, 107 6 55 U/kg/week; he-
matocrit, 31.8 6 1.8%) and maintenance phase (rHuEPO,
54 6 25 U/kg/week; hematocrit, 31.1 6 1.3%) in eight
hemodialysis patients with thalassemia (6 a-thalassemia expensive than normal. To reduce the dose require-
trait and 2 b-thalassemia minor) [40]. Iron deficiency ments, treatment options such as a change from hemodi-
developed at the inception of or during rHuEPO therapy alysis to CAPD or renal transplantation, and from an
in our patients. The early and prompt iron supplementa- intravenous to subcutaneous administration route should
tion can certainly promote reductions in rHuEPO dose. be considered for hemodialysis patients with hemoglo-
Because iron deficiency is the most important factor of binopathy and high-dose rHuEPO resistance.
hyporesponsiveness to rHuEPO, it might have been un-
Inflammatory states and infectionsderdiagnosed in some of the previously reported patients
with a- or b-thalassemia. Despite the fact that a favorable Patients with acute or chronic inflammatory disease
response was reported in our study, rHuEPO hypore- frequently present with a remarkable resistance to the
sponsiveness was still noted in some thalassemic patients effects of rHuEPO. The inflammatory state may be obvi-
on chronic dialysis [39, 110, 111]. A further increase in ous after surgery or tuberculous arthritis [25], or indolent
rHuEPO doses is usually required to achieve an optimal in perinephric abscess [26], vasculitis [27], occult rejec-
response in these patients. tion in a failed graft [28, 114], and uremic pericarditis
[29]. Plasma C-reactive protein (CRP) is a useful markerHemoglobinopathies and chronic hemolysis
for confirming and quantitating the severity of inflam-
Besides thalassemia, sickle cell exhibits an additional mation in patients undergoing dialysis [28, 29, 115, 116].
cause for anemia in patients with chronic renal failure An increase in plasma CRP probably best reflects the
disease [36, 112, 113]. We reported a hemodialysis pa- inflammatory state or infections in dialysis patients.
tient with rHuEPO resistance and hemoglobinopathy Therefore, it is prudent to determine plasma CRP to rule
J-Meinung [37], which was initially found by hemoglobin out the presence of an underlying inflammation in patients
electrophoresis and finally proven by molecular genetic of unexplained poor responses to rHuEPO (Fig. 3). Early
analysis. Our patient had splenomegaly, an increased detection and prompt management, if possible, can re-
serum bilirubin and reticulocyte index, and a reduced store the responsiveness to rHuEPO and reduce the dose
haptoglobin level, which are hallmarks of chronic active requirements [27–29].
hemolysis. As the major cause of anemia is hemolysis in
patients of hemoglobinopathy and ESRD, rHuEPO in
IRON OVERLOADthe usual doses may not be effective in correcting anemia.
Iron excess in dialysis patients may be represented byLarger doses are required for an optimal response in
these individuals; however, the treatment cost is more a serum ferritin level of more than 500 mg/liter as pro-
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Fig. 4. Evolution of the hematocrit, recombinant human erythropoietin dose (EPO), transferrin saturation, and erythrocyte zinc protoporphyrin
(ZPP) in 12 hemodialysis patients treated with eight weeks of ascorbic acid (d, ) and in 12 hemodialysis patients not receiving ascorbic acid
treatment (s, h). Statistical analysis is conducted by a two-way analysis of variance with repeated measures. *P , 0.05 vs. baseline.
posed by Anastassiades et al [117], more than 800 mg/ els of more than 500 mg/liter may have functional iron
deficiency and respond to i.v. iron therapy [52, 91, 118],liter as found by Macdougall et al [118], or more than
1000 mg/liter as proposed by Eschbach et al [119]. Iron but this beneficial effect was not observed by Rosenlo¨f
et al [83] and our preliminary study (unpublished data).overload not only increases the cardiovascular and infec-
tious morbidity in dialysis patients but sometimes may Even i.v. iron therapy can circumvent this resistance; iron
supplementation could worsen hemosiderosis in iron-cause relative resistance to rHuEPO. El-Reshaid et al
showed that the rHuEPO dose in the maintenance phase overloaded patients. El-Reshaid et al declared that iron
supplementation is not warranted in these patients [120].is nearly twice as large in iron-overloaded patients (ferri-
tin more than 1100 mg/liter) as in controls (ferritin 100 The risks related to iron overload do not justify this
treatment option. In fact, rHuEPO is an effective treat-to 600 mg/liter) [120]. Interestingly, TS decreased to a
level of less than 30% in six of 11 iron-overloaded pa- ment for iron overload. It is rational to increase the dose
by an escalation method in these patients if other factorstients at the end of their study. The mechanism of this
form of rHuEPO hyporesponsiveness is not yet fully pertaining to inadequate rHuEPO response do not exist.
However, this should be balanced by the cost of high-understood, but inadequate iron mobilization and defec-
tive iron utilization are the possible reasons. Ali et al dose rHuEPO therapy. Therefore, an adjuvant therapy
is needed not only to improve the rHuEPO responsedisclosed that 10 hemodialysis patients with a mean ferri-
tin level of 1336 mg/liter have depleted marrow iron but also to avoid the inadvertent hazard.
It has been demonstrated that rHuEPO resistance duestores [85]. Figure 1 also shows that a serum ferritin level
of more than 300 mg/liter does not exclude functional to functional iron deficiency in four hemodialysis pa-
tients with iron overload (ferritin of more than 500 mg/iron deficiency.
Several studies reported that patients with ferritin lev- liter) can be overcome by i.v. ascorbic acid therapy (500
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mg, one to three times per week) in a preliminary study patients with an inadequate response (Figs. 1 and 3).
Further research is needed to resolve the following prob-[121]. To elucidate the possible mechanisms further, 24
hemodialysis patients with serum ferritin levels of more lems: (a) the optimal diagnostic testing for iron defi-
ciency, (b) the upper limit of serum ferritin or TS tothan 500 mg/liter were enrolled in our study [122]. Twelve
patients failed to achieve the target hematocrit level of avoid iron overload during i.v. iron therapy, and (c) the
adjuvant therapy other than iron supplementation for30% in spite of a rHuEPO dose of more than 150 U/kg/
week. Ascorbic acid (300 mg) is administered intrave- rHuEPO in hemodialysis patients with iron overload.
nously postdialysis three times per week for eight weeks
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